Type I IFNs and their role in the development of autoimmune diseases

Laura M. Burdick, Najwa Somani, Ally-Khan Somani

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Since their initial use in the 1980s, IFNs have become an essential component of the therapy for many diseases such as hepatitis and multiple sclerosis. Although they have been extremely useful in conditions that pose therapeutic challenges, complications associated with their use have been widely reported including emerging reports of several autoimmune diseases. Many of these reports have shed light on the pathogenesis of autoimmune disorders and helped to highlight not only the critical role of type I IFNs in defense against viral infections but also the pivotal role they occupy in the interface between innate and adaptive immunity. Many patients with autoimmune disease have increased responsiveness to type I IFNs (α/β), and therapy with these cytokines has induced or unmasked autoimmune disease in many additional patients. Objective: The objective of this paper is to discuss the role of type I IFNs in autoimmunity. Methods: The literature regarding type I IFNs and autoimmunity was reviewed using the Medline database from 1950 to 2009. Search terms included 'interferon alpha' and 'autoimmune disease' and 'interferon beta' and 'autoimmune disease'. Case reports, case series, reviews and prospective studies were included in the analysis. Results/conclusions: In the literature a variety of autoimmune disorders have reportedly been induced by the use of type I IFNs, being used, although these are primarily in the form of case reports and case series. Nevertheless, there is a growing body of molecular evidence to support the clinical association. The role of IFNs in the induction of autoimmunity is complex with interplay of many genetic and environmental factors that influence the balance between normal and aberrant immune responsiveness, ultimately leading to the observed clinical manifestations.

Original languageEnglish (US)
Pages (from-to)459-472
Number of pages14
JournalExpert Opinion on Drug Safety
Volume8
Issue number4
DOIs
StatePublished - Jul 2009
Externally publishedYes

Fingerprint

Autoimmune Diseases
Autoimmunity
Interferon-beta
Adaptive Immunity
Virus Diseases
Innate Immunity
Interferon-alpha
Hepatitis
Multiple Sclerosis
Therapeutics
Databases
Prospective Studies
Cytokines

Keywords

  • Adverse effects
  • Autoimmune disease
  • Autoimmunity
  • IFN alpha
  • IFN beta
  • Type I IFN

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Type I IFNs and their role in the development of autoimmune diseases. / Burdick, Laura M.; Somani, Najwa; Somani, Ally-Khan.

In: Expert Opinion on Drug Safety, Vol. 8, No. 4, 07.2009, p. 459-472.

Research output: Contribution to journalArticle

Burdick, Laura M. ; Somani, Najwa ; Somani, Ally-Khan. / Type I IFNs and their role in the development of autoimmune diseases. In: Expert Opinion on Drug Safety. 2009 ; Vol. 8, No. 4. pp. 459-472.
@article{84edf0e96f4f45c7aa689e96647923a7,
title = "Type I IFNs and their role in the development of autoimmune diseases",
abstract = "Background: Since their initial use in the 1980s, IFNs have become an essential component of the therapy for many diseases such as hepatitis and multiple sclerosis. Although they have been extremely useful in conditions that pose therapeutic challenges, complications associated with their use have been widely reported including emerging reports of several autoimmune diseases. Many of these reports have shed light on the pathogenesis of autoimmune disorders and helped to highlight not only the critical role of type I IFNs in defense against viral infections but also the pivotal role they occupy in the interface between innate and adaptive immunity. Many patients with autoimmune disease have increased responsiveness to type I IFNs (α/β), and therapy with these cytokines has induced or unmasked autoimmune disease in many additional patients. Objective: The objective of this paper is to discuss the role of type I IFNs in autoimmunity. Methods: The literature regarding type I IFNs and autoimmunity was reviewed using the Medline database from 1950 to 2009. Search terms included 'interferon alpha' and 'autoimmune disease' and 'interferon beta' and 'autoimmune disease'. Case reports, case series, reviews and prospective studies were included in the analysis. Results/conclusions: In the literature a variety of autoimmune disorders have reportedly been induced by the use of type I IFNs, being used, although these are primarily in the form of case reports and case series. Nevertheless, there is a growing body of molecular evidence to support the clinical association. The role of IFNs in the induction of autoimmunity is complex with interplay of many genetic and environmental factors that influence the balance between normal and aberrant immune responsiveness, ultimately leading to the observed clinical manifestations.",
keywords = "Adverse effects, Autoimmune disease, Autoimmunity, IFN alpha, IFN beta, Type I IFN",
author = "Burdick, {Laura M.} and Najwa Somani and Ally-Khan Somani",
year = "2009",
month = "7",
doi = "10.1517/14740330903066726",
language = "English (US)",
volume = "8",
pages = "459--472",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Type I IFNs and their role in the development of autoimmune diseases

AU - Burdick, Laura M.

AU - Somani, Najwa

AU - Somani, Ally-Khan

PY - 2009/7

Y1 - 2009/7

N2 - Background: Since their initial use in the 1980s, IFNs have become an essential component of the therapy for many diseases such as hepatitis and multiple sclerosis. Although they have been extremely useful in conditions that pose therapeutic challenges, complications associated with their use have been widely reported including emerging reports of several autoimmune diseases. Many of these reports have shed light on the pathogenesis of autoimmune disorders and helped to highlight not only the critical role of type I IFNs in defense against viral infections but also the pivotal role they occupy in the interface between innate and adaptive immunity. Many patients with autoimmune disease have increased responsiveness to type I IFNs (α/β), and therapy with these cytokines has induced or unmasked autoimmune disease in many additional patients. Objective: The objective of this paper is to discuss the role of type I IFNs in autoimmunity. Methods: The literature regarding type I IFNs and autoimmunity was reviewed using the Medline database from 1950 to 2009. Search terms included 'interferon alpha' and 'autoimmune disease' and 'interferon beta' and 'autoimmune disease'. Case reports, case series, reviews and prospective studies were included in the analysis. Results/conclusions: In the literature a variety of autoimmune disorders have reportedly been induced by the use of type I IFNs, being used, although these are primarily in the form of case reports and case series. Nevertheless, there is a growing body of molecular evidence to support the clinical association. The role of IFNs in the induction of autoimmunity is complex with interplay of many genetic and environmental factors that influence the balance between normal and aberrant immune responsiveness, ultimately leading to the observed clinical manifestations.

AB - Background: Since their initial use in the 1980s, IFNs have become an essential component of the therapy for many diseases such as hepatitis and multiple sclerosis. Although they have been extremely useful in conditions that pose therapeutic challenges, complications associated with their use have been widely reported including emerging reports of several autoimmune diseases. Many of these reports have shed light on the pathogenesis of autoimmune disorders and helped to highlight not only the critical role of type I IFNs in defense against viral infections but also the pivotal role they occupy in the interface between innate and adaptive immunity. Many patients with autoimmune disease have increased responsiveness to type I IFNs (α/β), and therapy with these cytokines has induced or unmasked autoimmune disease in many additional patients. Objective: The objective of this paper is to discuss the role of type I IFNs in autoimmunity. Methods: The literature regarding type I IFNs and autoimmunity was reviewed using the Medline database from 1950 to 2009. Search terms included 'interferon alpha' and 'autoimmune disease' and 'interferon beta' and 'autoimmune disease'. Case reports, case series, reviews and prospective studies were included in the analysis. Results/conclusions: In the literature a variety of autoimmune disorders have reportedly been induced by the use of type I IFNs, being used, although these are primarily in the form of case reports and case series. Nevertheless, there is a growing body of molecular evidence to support the clinical association. The role of IFNs in the induction of autoimmunity is complex with interplay of many genetic and environmental factors that influence the balance between normal and aberrant immune responsiveness, ultimately leading to the observed clinical manifestations.

KW - Adverse effects

KW - Autoimmune disease

KW - Autoimmunity

KW - IFN alpha

KW - IFN beta

KW - Type I IFN

UR - http://www.scopus.com/inward/record.url?scp=67650552723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650552723&partnerID=8YFLogxK

U2 - 10.1517/14740330903066726

DO - 10.1517/14740330903066726

M3 - Article

VL - 8

SP - 459

EP - 472

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 4

ER -